COVID-19 infection has various presentations from respiratory to acute gastrointestinal symptoms. Several lines of evidence suggest that in addition to alveolar epithelial cells, enterocytes also express angiotensin-converting enzyme2 (ACE2) receptors, and SARS-CoV-2RNA has been demonstrated in the faeces of infected patients. This along with the fact that some patients (12-60% cases) particularly elderly people who have less diverse gut microbiota, experience diarrhea (resulting in a mild to severe dysbiosis) points out towards a possibility of gut-lung axis involvement in COVID-19. Dysbiosis is characterized by growth of opportunistic pathogens and a decrease in beneficial symbionts. Interestingly, the gut microbiota affect pulmonary health through a cross-talk with the lungs. Previous studies have shown that oral intake of probiotic strains like L. plantarum has immune modulatory activity in respiratory tract infections caused by influenza virus and rhinovirus and shorten duration of infection and decrease susceptibility to pathogens. These effects are attributable to activation of CD8+ T cells, reduction of pro-inflammatory and elevation of anti-inflammatory cytokines. Moreover, some studies have shown that gut microbiota can downregulate intestinal ACE2 receptors expression. Hence it seems logically that normalization of intestinal dysbiosis using probiotics can be effective for the control of COVID-19. As cytokine storm occur in patients with severe COVID-19, the effect of probiotics on pro-inflammatory cytokines allows viral clearance and minimize immune response-mediated tissue damage in the lungs and other organs. Decreased gastrointestinal complications, lower mortality, and shortened ICU stays are the other impacts. In the context of COVID-19, the use of probiotics may be a promising adjunctive therapy to help in the improvement of prophylaxis and accelerate recovery and improve clinical outcomes. However, due to the risk of probiotics-sepsis, it has been suggested to practice caution while using probiotics in the presence of a major risk factor like premature infants or immune-compromised state.